Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus observation as adjuvant therapy after surgery for high-risk muscle-invasive urothelial carcinoma
MOH_2017-06-05_000489Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Roche. Started Oct 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on MOH_2017-06-05_000489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-05_000489.